Clinical significance of mitochondrial DNA content in acute promyelocytic leukaemia
© 2022 British Society for Haematology and John Wiley & Sons Ltd..
Although a growing body of evidence demonstrates that altered mtDNA content (mtDNAc) has clinical implications in several types of solid tumours, its prognostic relevance in acute promyelocytic leukaemia (APL) patients remains largely unknown. Here, we show that patients with higher-than-normal mtDNAc had better outcomes regardless of tumour burden. These results were more evident in patients with low-risk of relapse. The multivariate Cox proportional hazard model demonstrated that high mtDNAc was independently associated with a decreased cumulative incidence of relapse. Altogether, our data highlights the possible role of mitochondrial metabolism in APL patients treated with ATRA.
| Errataetall: |
CommentIn: Br J Haematol. 2023 Jan;200(2):126-127. - PMID 36342482 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:200 |
|---|---|
| Enthalten in: |
British journal of haematology - 200(2023), 2 vom: 22. Jan., Seite 170-174 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
5688UTC01R |
|---|
| Anmerkungen: |
Date Completed 13.01.2023 Date Revised 08.02.2023 published: Print-Electronic CommentIn: Br J Haematol. 2023 Jan;200(2):126-127. - PMID 36342482 Citation Status MEDLINE |
|---|
| doi: |
10.1111/bjh.18510 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347782701 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347782701 | ||
| 003 | DE-627 | ||
| 005 | 20231226034644.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bjh.18510 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1159.xml |
| 035 | |a (DE-627)NLM347782701 | ||
| 035 | |a (NLM)36263593 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pereira-Martins, Diego A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical significance of mitochondrial DNA content in acute promyelocytic leukaemia |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.01.2023 | ||
| 500 | |a Date Revised 08.02.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Br J Haematol. 2023 Jan;200(2):126-127. - PMID 36342482 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 British Society for Haematology and John Wiley & Sons Ltd. | ||
| 520 | |a Although a growing body of evidence demonstrates that altered mtDNA content (mtDNAc) has clinical implications in several types of solid tumours, its prognostic relevance in acute promyelocytic leukaemia (APL) patients remains largely unknown. Here, we show that patients with higher-than-normal mtDNAc had better outcomes regardless of tumour burden. These results were more evident in patients with low-risk of relapse. The multivariate Cox proportional hazard model demonstrated that high mtDNAc was independently associated with a decreased cumulative incidence of relapse. Altogether, our data highlights the possible role of mitochondrial metabolism in APL patients treated with ATRA | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a ATRA | |
| 650 | 4 | |a anthracycline-based chemotherapy | |
| 650 | 4 | |a mtDNA content | |
| 650 | 4 | |a oxidative phosphorylation | |
| 650 | 7 | |a Tretinoin |2 NLM | |
| 650 | 7 | |a 5688UTC01R |2 NLM | |
| 650 | 7 | |a DNA, Mitochondrial |2 NLM | |
| 700 | 1 | |a Coelho-Silva, Juan L |e verfasserin |4 aut | |
| 700 | 1 | |a Weinhäuser, Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Franca-Neto, Pedro L |e verfasserin |4 aut | |
| 700 | 1 | |a Silveira, Douglas R |e verfasserin |4 aut | |
| 700 | 1 | |a Ortiz, César |e verfasserin |4 aut | |
| 700 | 1 | |a Moreira-Aguiar, Amanda |e verfasserin |4 aut | |
| 700 | 1 | |a Lima, Marinus M |e verfasserin |4 aut | |
| 700 | 1 | |a Koury, Luisa C |e verfasserin |4 aut | |
| 700 | 1 | |a de Melo, Raul A |e verfasserin |4 aut | |
| 700 | 1 | |a Glória, Ana B |e verfasserin |4 aut | |
| 700 | 1 | |a Fagundes, Evandro M |e verfasserin |4 aut | |
| 700 | 1 | |a Lino, Bruno K |e verfasserin |4 aut | |
| 700 | 1 | |a Pagnano, Katia |e verfasserin |4 aut | |
| 700 | 1 | |a Bittencourt, Rosane |e verfasserin |4 aut | |
| 700 | 1 | |a Nunes, Elenaide |e verfasserin |4 aut | |
| 700 | 1 | |a Traina, Fabiola |e verfasserin |4 aut | |
| 700 | 1 | |a Figueiredo-Pontes, Lorena |e verfasserin |4 aut | |
| 700 | 1 | |a Keating, Armand |e verfasserin |4 aut | |
| 700 | 1 | |a Tallman, Martin S |e verfasserin |4 aut | |
| 700 | 1 | |a Ribeiro, Raul C |e verfasserin |4 aut | |
| 700 | 1 | |a Dilon, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Ganser, Arnold |e verfasserin |4 aut | |
| 700 | 1 | |a Sanz, Miguel A |e verfasserin |4 aut | |
| 700 | 1 | |a Berliner, Nancy |e verfasserin |4 aut | |
| 700 | 1 | |a Valk, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Löwenberg, Bob |e verfasserin |4 aut | |
| 700 | 1 | |a Ottone, Tiziana |e verfasserin |4 aut | |
| 700 | 1 | |a Noguera, Nelida I |e verfasserin |4 aut | |
| 700 | 1 | |a Voso, Maria T |e verfasserin |4 aut | |
| 700 | 1 | |a Paoloni, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Fazi, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Ammatuna, Emanuele |e verfasserin |4 aut | |
| 700 | 1 | |a Huls, Gerwin |e verfasserin |4 aut | |
| 700 | 1 | |a Schuringa, Jan Jacob |e verfasserin |4 aut | |
| 700 | 1 | |a Rego, Eduardo M |e verfasserin |4 aut | |
| 700 | 1 | |a Lucena-Araujo, Antonio R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of haematology |d 1955 |g 200(2023), 2 vom: 22. Jan., Seite 170-174 |w (DE-627)NLM000000396 |x 1365-2141 |7 nnns |
| 773 | 1 | 8 | |g volume:200 |g year:2023 |g number:2 |g day:22 |g month:01 |g pages:170-174 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/bjh.18510 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 200 |j 2023 |e 2 |b 22 |c 01 |h 170-174 | ||